subpage_img01subpage_img02subpage_img03filler
People|Funding Opportunities|Policies|Reports
 

Research Policy and Compliance

bar

Embryonic Stem Cell Research Oversight

Harvard's Embryonic Stem Cell Research Oversight (ESCRO) Committee shall provide oversight of all issues related to the use of human embryos, human oocytes, the derivation and use of human embryonic stem cell (hESC) lines, and the use of hESC derivatives at Harvard University, including research that uses pre-existing anonymous hES cell lines that may not require consideration by an Institutional Review Board (IRB).

Review and approval by the ESCRO Committee is required regardless of the source of funding or the applicability of state or federal law. It is required in addition to other approvals that may be required by law or insitutional policy, including but not limited to Institutional Review Boards (IRBs), Institutional Animal Care and Use Committees (IACUCs), Institutional Biosafety Committees (at Harvard, the Committee on Microbiological Safety), and administrative approval at the school level, including documentation of the school's approval of a cost allocation methodology. The ESCRO Committee shall have final approval, and its approval will be contingent on the satisfaction of all other approvals required. No University official will approve research under the ESCRO Committee's oversight without prior review and approval by the Committee.

For more information, please visit the ESCRO Committee's website at escro.harvard.edu.

Supported by WDS